文献速递类风湿关节炎

韩国类风湿关节炎患者接受Janus激酶抑制剂治疗后的静脉血栓栓塞风险:一项全国性人群研究

Risk of venous thromboembolism in Korean patients with rheumatoid arthritis treated with Janus kinase inhibitors: A nationwide population-based study.
PubMed 文献 · Semin Arthritis Rheum · 2023-05-05

该研究利用韩国国民健康保险服务数据库(2015-2019年),纳入4,178例从未接受靶向治疗的类风湿关节炎患者,比较JAK抑制剂(871例)与TNF抑制剂(3,307例)使用者的静脉血栓栓塞风险。经稳定化逆概率治疗加权(sIPTW)平衡后,JAK抑制剂组VTE发生率为0.06/100人年(95%CI 0.00-1.23),TNF抑制剂组为0.38/100人年(95%CI 0.25-0.58),校正后风险比HR 0.18(95%CI 0.01-3.47)。结论认为在韩国RA患者中,与TNF抑制剂相比,JAK抑制剂治疗未增加VTE风险。

要点

  • JAK抑制剂组VTE发生率为0.06/100人年(95%CI 0.00-1.23),TNF抑制剂组为0.38/100人年(95%CI 0.25-0.58)。
  • sIPTW后校正非平衡变量的HR为0.18(95%CI 0.01-3.47)。
  • 结论认为韩国RA患者中JAK抑制剂较TNF抑制剂未增加VTE风险。

核心结论

  • 在韩国类风湿关节炎患者中,与TNF抑制剂相比,JAK抑制剂治疗未增加静脉血栓栓塞风险。

研究设计与样本

  • 利用韩国国民健康保险服务数据库(2015-2019年)开展的全国性人群研究。
  • 纳入从未接受靶向治疗的类风湿关节炎患者,分为JAK抑制剂组(871例)和TNF抑制剂组(3,307例)。
  • 排除30天内发生过任何VTE事件或使用抗凝剂的患者。
  • 采用基于倾向评分的稳定化逆概率治疗加权(sIPTW)平衡人口学与临床特征。
  • 采用考虑死亡为竞争风险的Cox比例风险模型评估VTE风险。

主要发现

  • JAK抑制剂组随访1,029.2人年,TNF抑制剂组随访5,940.3人年。
  • sIPTW平衡后,JAK抑制剂组VTE发生率为0.06/100人年(95%CI 0.00-1.23),TNF抑制剂组为0.38/100人年(95%CI 0.25-0.58)。
  • sIPTW后校正非平衡变量的风险比HR为0.18(95%CI 0.01-3.47)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: There was a safety concern about an increased risk of thromboembolic events in patients with rheumatoid arthritis (RA) treated with Janus kinase inhibitors (JAKis). This study aimed to determine the risk of venous thromboembolism (VTE) in Korean patients with RA treated with JAKis compared with tumour necrosis factor (TNF) inhibitors. METHODS: Using the National Health Insurance Service database between 2015 and 2019, patients with prevalent RA who started JAKi or TNF inhibitor were selected as the study population. All participants were naïve to targeted therapy. Patients that had experienced any VTE event or used anticoagulant agents within 30 days were excluded. Demographic and clinical characteristics were all balanced by stabilised inverse probability of treatment weighting (sIPTW) using propensity score. The Cox proportional hazard model considering death as a competing risk was used to evaluate the risk of VTE in JAKi users compared with TNF inhibitor users. RESULTS: A total of 4,178 patients were included: 871 JAKi users and 3,307 TNF inhibitor users were followed up for 1,029.2 person-years (PYs) and 5,940.3 PYs, respectively. With a balanced sample after sIPTW, the incidence rates (IR) of VTE were 0.06 per 100 PYs (95% confidence interval [CI] 0.00-1.23) in JAKi users and 0.38 per 100 PYs (95% CI 0.25-0.58) in TNF inhibitor users. The hazard ratio was 0.18 (95% CI 0.01-3.47) after adjusting for unbalanced variables after performing sIPTW. CONCLUSION: There is no increased risk of VTE in RA patients treated with JAKis compared with TNF inhibitors in Korea.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Song YJ, Cho SK, Kim JY, et al. Risk of venous thromboembolism in Korean patients with rheumatoid arthritis treated with Janus kinase inhibitors: A nationwide population-based study. Semin Arthritis Rheum. 2023. PMID: 37172496. doi:10.1016/j.semarthrit.2023.152214

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。